Ibrutinib, a BTK inhibitor, provides a significant overall survival benefit and progression-free survival in CLL by irreversibly inhibiting the BTK pathway, leading to a significant reduction in survival and proliferation of malignant B cells [3,4]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.